

# Lucrezia Hausner

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11677690/publications.pdf>

Version: 2024-02-01

44  
papers

3,720  
citations

331670

21  
h-index

302126

39  
g-index

44  
all docs

44  
docs citations

44  
times ranked

5535  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	7.4	1,166
2	New insights into the genetic etiology of Alzheimer's disease and related dementias. Nature Genetics, 2022, 54, 412-436.	21.4	700
3	Mild cognitive impairment and deficits in instrumental activities of daily living: a systematic review. Alzheimer's Research and Therapy, 2015, 7, 17.	6.2	419
4	SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease. Molecular Neurodegeneration, 2014, 9, 53.	10.8	216
5	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	12.8	140
6	Association of Cerebral Amyloid- $\beta$ Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	11.0	133
7	Efficacy and Cognitive Side Effects of Electroconvulsive Therapy (ECT) in Depressed Elderly Inpatients With Coexisting Mild Cognitive Impairment or Dementia. Journal of Clinical Psychiatry, 2011, 72, 91-97.	2.2	98
8	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	9.0	97
9	Predicting Prodromal Alzheimer's Disease in Subjects with Mild Cognitive Impairment Using Machine Learning Classification of Multimodal Multicenter Diffusion Tensor and Magnetic Resonance Imaging Data. Journal of Neuroimaging, 2015, 25, 738-747.	2.0	79
10	Detection of Retinal Nerve Fiber Layer Defects in Alzheimer's Disease Using SD-OCT. Frontiers in Psychiatry, 2014, 5, 22.	2.6	77
11	Basal Forebrain and Hippocampus as Predictors of Conversion to Alzheimer's Disease in Patients with Mild Cognitive Impairment - A Multicenter DTI and Volumetry Study. Journal of Alzheimer's Disease, 2015, 48, 197-204.	2.6	56
12	The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey. Alzheimer's and Dementia, 2015, 11, 195.	0.8	56
13	Targeted Mass Spectrometry Suggests Beta-Synuclein as Synaptic Blood Marker in Alzheimer's Disease. Journal of Proteome Research, 2020, 19, 1310-1318.	3.7	43
14	The European DTI Study on Dementia - A multicenter DTI and MRI study on Alzheimer's disease and Mild Cognitive Impairment. NeuroImage, 2017, 144, 305-308.	4.2	33
15	Relation of Odor Identification with Alzheimer's Disease Markers in Cerebrospinal Fluid and Cognition. Journal of Alzheimer's Disease, 2017, 60, 1025-1034.	2.6	33
16	Development of a Proxy-Free Objective Assessment Tool of Instrumental Activities of Daily Living in Mild Cognitive Impairment Using Smart Home Technologies. Journal of Alzheimer's Disease, 2016, 52, 509-517.	2.6	32
17	Structured relearning of activities of daily living in dementia: the randomized controlled REDALI-DEM trial on errorless learning. Alzheimer's Research and Therapy, 2017, 9, 22.	6.2	31
18	Beta-synuclein in cerebrospinal fluid as an early diagnostic marker of Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 349-356.	1.9	31

#	ARTICLE	IF	CITATIONS
19	Association of Rare <i>APOE</i> Missense Variants V236E and R251G With Risk of Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 652.	9.0	31
20	Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1119-1128.	2.6	27
21	Comparison of Visual Evoked Potentials and Retinal Nerve Fiber Layer Thickness in Alzheimer's Disease. <i>Frontiers in Neurology</i> , 2013, 4, 203.	2.4	21
22	Electroconvulsive therapy selectively enhances amyloid $\beta$ 1-42 in the cerebrospinal fluid of patients with major depression: A prospective pilot study. <i>European Neuropsychopharmacology</i> , 2016, 26, 1877-1884.	0.7	20
23	Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 324-333.	2.7	19
24	Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 51-64.	2.6	18
25	Bupropion for the Treatment of Apathy in Alzheimer Disease. <i>JAMA Network Open</i> , 2020, 3, e206027.	5.9	18
26	Severe agitation in severe early-onset Alzheimer's disease resolves with ECT. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 2147.	2.2	14
27	Evaluation of Sodium ( $^{23}\text{Na}$ ) MR-imaging as a Biomarker and Predictor for Neurodegenerative Changes in Patients With Alzheimer's Disease. <i>In Vivo</i> , 2021, 35, 429-435.	1.3	14
28	Don't forget about tau: the effects of ApoE4 genotype on Alzheimer's disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairment" data from the Dementia Competence Network. <i>Journal of Neural Transmission</i> , 2022, 129, 477-486.	2.8	14
29	Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 639-652.	2.6	12
30	Association of lysophosphatidic acids with cerebrospinal fluid biomarkers and progression to Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 124.	6.2	12
31	Regional Variation on the Presentation of Alzheimer's Disease Patients in Memory Clinics within Europe: Data from the ICTUS Study. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 155-165.	2.6	10
32	Separating Symptomatic Alzheimer's Disease from Depression based on Structural MRI. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 353-363.	2.6	10
33	Clinical characterization of a presenilin 1 mutation (F177S) in a family with very early-onset Alzheimer's disease in the third decade of life. , 2014, 10, e27-e39.		9
34	Late-onset major depression is associated with age-related white matter lesions in the brainstem. <i>International Journal of Geriatric Psychiatry</i> , 2017, 32, 446-454.	2.7	7
35	Case report: a giant arachnoid cyst masking Alzheimer's disease. <i>BMC Psychiatry</i> , 2019, 19, 274.	2.6	7
36	Tablet-based sensorimotor home-training system for amnesic mild cognitive impairments in the elderly: design of a randomised clinical trial. <i>BMJ Open</i> , 2019, 9, e028632.	1.9	5

#	ARTICLE	IF	CITATIONS
37	Crossed Cerebellar Diaschisis in Alzheimer's Disease Detected by Arterial Spin-labelling Perfusion MRI. <i>In Vivo</i> , 2021, 35, 1177-1183.	1.3	5
38	Promoting neuroplasticity and neuropsychological functioning in frailty through an app-based sensorimotor training: study protocol for a randomized trial. <i>BMC Geriatrics</i> , 2021, 21, 343.	2.7	3
39	Should electroconvulsive therapy be more routinely used in the treatment of depression in elderly patients with cognitive disturbances?. <i>Neuropsychiatry</i> , 2011, 1, 403-407.	0.4	1
40	IC-P-072: PREDICTION OF PRODROMAL AD IN MCI SUBJECTS USING MULTICENTER DTI AND MRI DATA AND MULTIPLE KERNELS SVM: AN EDSO STUDY. , 2014, 10, P40-P40.		1
41	P1-255: PREDICTION OF PRODROMAL AD IN MCI SUBJECTS USING MULTICENTER DTI AND MRI DATA AND MULTIPLE KERNELS SVM: AN EDSO STUDY. , 2014, 10, P400-P401.		1
42	Rapid Support for Older Adults during the Initial Stages of the COVID-19 Pandemic: Results from a Geriatric Psychiatry Helpline. <i>Geriatrics (Switzerland)</i> , 2021, 6, 30.	1.7	1
43	P1-298: CEREBROSPINAL FLUID AND PLASMA LEVELS OF LYOPHOSPHATIDIC ACIDS (LPAS) ASSOCIATE WITH CEREBROSPINAL FLUID A $\beta$ 42 AND $\tau$ . <i>Alzheimer's and Dementia</i> , 2018, 14, P403.	0.8	0
44	6 .Diagnostische Methoden. , 2018, , 187-352.		0